Dow Jones

38 589,16

-0,15%

DAX

Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

SGEN

Seagen (SGEN)

Seagen Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:SGEN

1 2 3 4 5 6 7 8 9 10 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
09/01/2024	12h12	IH Market News	Wall Street Highlights: HPE and Juniper Networks in Negotiations, Elliott Invests $1 Billion in Match Group, and More	NASDAQ:SGEN	Seagen Inc
26/12/2023	12h12	Edgar (US Regulatory)	Form 15-12G - Securities registration termination [Section 12(g)]	NASDAQ:SGEN	Seagen Inc
19/12/2023	00h46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SGEN	Seagen Inc
18/12/2023	23h25	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:SGEN	Seagen Inc
15/12/2023	23h00	PR Newswire (US)	PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer	NASDAQ:SGEN	Seagen Inc
14/12/2023	14h47	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:SGEN	Seagen Inc
14/12/2023	14h29	Edgar (US Regulatory)	Form POSASR - Post-effective Amendment to an automatic shelf registration statement	NASDAQ:SGEN	Seagen Inc
14/12/2023	14h00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SGEN	Seagen Inc
14/12/2023	14h00	Edgar (US Regulatory)	Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities	NASDAQ:SGEN	Seagen Inc
12/12/2023	13h43	Dow Jones News	Pfizer to Close $43 Billion Seagen Acquisition This Week	NASDAQ:SGEN	Seagen Inc
11/12/2023	01h30	Business Wire	ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma	NASDAQ:SGEN	Seagen Inc
06/12/2023	14h15	Business Wire	TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer	NASDAQ:SGEN	Seagen Inc
01/12/2023	00h04	Dow Jones News	Astellas, Seagen: Cancer Treatment Padcev Supplemental Biologics License Application Gets FDA Priority Review	NASDAQ:SGEN	Seagen Inc
30/11/2023	23h00	Business Wire	FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	NASDAQ:SGEN	Seagen Inc
14/11/2023	03h37	Edgar (US Regulatory)	Form 144/A - Report of proposed sale of securities: [Amend]	NASDAQ:SGEN	Seagen Inc
14/11/2023	00h37	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SGEN	Seagen Inc
03/11/2023	17h00	Business Wire	Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting	NASDAQ:SGEN	Seagen Inc
02/11/2023	18h00	Business Wire	New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate	NASDAQ:SGEN	Seagen Inc
01/11/2023	13h31	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SGEN	Seagen Inc
01/11/2023	13h00	Business Wire	Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress	NASDAQ:SGEN	Seagen Inc
22/10/2023	16h30	Business Wire	TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial	NASDAQ:SGEN	Seagen Inc
22/10/2023	16h30	Business Wire	Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer	NASDAQ:SGEN	Seagen Inc
20/10/2023	13h22	IH Market News	Friday’s Wall Street Highlights: SolarEdge, Intuitive Surgical, Knight-Swift, HPE, and more	NASDAQ:SGEN	Seagen Inc
16/10/2023	14h00	Business Wire	Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023	NASDAQ:SGEN	Seagen Inc
12/10/2023	14h00	Business Wire	Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023	NASDAQ:SGEN	Seagen Inc
22/09/2023	13h02	Dow Jones News	Merck, Seagen, Astellas Phase 3 Bladder Cancer Study Hits Endpoints	NASDAQ:SGEN	Seagen Inc
22/09/2023	11h00	Business Wire	PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial	NASDAQ:SGEN	Seagen Inc
18/09/2023	13h25	IH Market News	Monday’s Wall Street Highlights: Cisco Systems, GM, Alibaba, SVB Financial, Clorox and More	NASDAQ:SGEN	Seagen Inc
04/09/2023	21h00	Business Wire	Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone	NASDAQ:SGEN	Seagen Inc
04/09/2023	21h00	Business Wire	Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy	NASDAQ:SGEN	Seagen Inc